Ann: Emyria Pursuing Registration of EMD-003 in CY2021, page-8

As for collecting data to support it EMD is way ahead as it seems a key part of their business model however there are two companies on my radar that could shake things up on the <150 mg per day ruling.


Without getting off topic..

NTI is set to commence human trials Q1 2021

Point of difference is they are using a very scientific approach studying CBDA, CBDP and CBDB in lab settings (Not so RWE.. so far) but by focusing of strains of cannabis with minimal THC (<.03%) and having high concentrations of specific CBDA, CBDP and CBDB they are getting far greater results with low medication dosages. Also they are tackling autism, epilepsy and ADHD.

AVE has commenced human trials 23/12/2020

Their unique IP TPM® seems to be a product to coexist with CBD medicines to help with bio-availability (helping low dose CBD absorb into the stomach more efficiently). Huge point of difference is their product is to help CBD medicines with efficiency, I am not sure if they plan to sell the IP/product to external medicine manufacturers or create their own CBD medicines.

This could disrupt everything by allowing lower dosages to be more effective basically giving manufacturers a cheat code to achieve that bottom line of <150 mg per day.


Disclosure, I have no qualifications regarding the above, this just my opinion.